BSEM — Biostem Technologies Cashflow Statement
0.000.00%
Last trade - 00:00- $75.72m
- $49.17m
- $47.48m
Annual cashflow statement for Biostem Technologies, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | PRESS | ARS | ARS |
| Standards: | USG | USG | — | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -2.37 | -1.41 | -7.86 | 31 | -6.58 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 0.628 | -0.142 | 7.22 | 8.55 | 16.3 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.916 | 0.642 | -3.08 | -11.3 | -3.98 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -0.582 | -0.625 | -3.5 | 24.5 | 9.94 |
| Capital Expenditures | — | — | -0.21 | -0.427 | -3.35 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | 0.061 | — | -1.25 | 1.25 |
| Sale of Fixed Assets | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | — | 0.061 | -0.21 | -1.68 | -2.1 |
| Financing Cash Flow Items | — | — | — | 0 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 0.542 | 0.804 | 3.18 | -0.195 | -1.12 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.04 | 0.24 | -0.533 | 22.6 | 6.72 |